MAP Pharmaceuticals Inc., a Mountain View, Calif.-based developer of inhaled drug products for respiratory and CNS diseases, has raised has raised $50 million in Series D funding. D.E. Shaw Group was joined by return backers Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital and Skyline Ventures.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
